98.01

2.85% 2.60

Illumina Inc (ILMN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ILMN? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$95.41

Offen:

$95.005

24-Stunden-Volumen:

1.22M

Relative Volume:

0.56

Marktkapitalisierung:

$13.93B

Einnahmen:

$4.34B

Nettoeinkommen (Verlust:

$-965.00M

KGV:

-16.15

EPS:

-6.07

Netto-Cashflow:

$869.00M

1W Leistung:

+7.23%

1M Leistung:

+19.32%

6M Leistung:

-26.56%

1J Leistung:

-6.98%

1-Tages-Spanne:

$95.00

$100.15

1-Wochen-Bereich:

$90.30

$100.15

52-Wochen-Spanne:

$68.70

$156.66

Illumina Inc Stock (ILMN) Company Profile

Firmenname

Illumina Inc

Sektor

Healthcare (1174)

Branche

Diagnostics & Research (54)

Telefon

(858) 202-4500

Adresse

5200 ILLUMINA WAY, SAN DIEGO, CA

Mitarbeiter

8,970

Twitter

@illumina

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

ILMN's Discussions on Twitter

Vergleichen Sie ILMN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ILMN Illumina Inc	98.15	13.93B	4.34B	-965.00M	869.00M	-6.07
TMO Thermo Fisher Scientific Inc	420.35	156.49B	42.90B	6.52B	6.72B	17.05
DHR Danaher Corp	201.10	145.01B	23.82B	3.77B	4.90B	5.15
IDXX Idexx Laboratories Inc	542.09	42.30B	3.93B	894.97M	837.70M	10.82
A Agilent Technologies Inc	120.94	34.24B	6.63B	1.17B	1.19B	4.05
IQV Iqvia Holdings Inc	163.01	27.64B	15.50B	1.33B	2.16B	7.34

Illumina Inc Stock (ILMN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-04	Bestätigt	Citigroup	Neutral
2025-02-28	Herabstufung	HSBC Securities	Buy → Hold
2025-02-10	Herabstufung	Barclays	Equal Weight → Underweight
2025-02-07	Herabstufung	TD Cowen	Buy → Hold
2024-12-11	Herabstufung	Citigroup	Buy → Neutral
2024-11-12	Fortgesetzt	Morgan Stanley	Equal-Weight
2024-10-17	Hochstufung	HSBC Securities	Hold → Buy
2024-08-28	Hochstufung	Argus	Hold → Buy
2024-08-16	Hochstufung	Daiwa Securities	Neutral → Buy
2024-08-14	Hochstufung	Barclays	Underweight → Equal Weight
2024-08-14	Hochstufung	TD Cowen	Hold → Buy
2024-07-10	Hochstufung	Citigroup	Neutral → Buy
2024-06-03	Fortgesetzt	Jefferies	Hold
2024-01-16	Herabstufung	HSBC Securities	Buy → Hold
2024-01-04	Herabstufung	TD Cowen	Outperform → Market Perform
2023-12-18	Hochstufung	Scotiabank	Sector Perform → Sector Outperform
2023-12-15	Hochstufung	Bernstein	Underperform → Mkt Perform
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-14	Eingeleitet	Stephens	Overweight
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-12-12	Herabstufung	BofA Securities	Neutral → Underperform
2023-12-11	Hochstufung	Citigroup	Sell → Neutral
2023-11-10	Herabstufung	Canaccord Genuity	Buy → Hold
2023-09-28	Eingeleitet	Bernstein	Underperform
2023-07-05	Fortgesetzt	JP Morgan	Neutral
2023-01-25	Herabstufung	Argus	Buy → Hold
2023-01-05	Eingeleitet	Scotiabank	Sector Perform
2022-12-12	Herabstufung	Citigroup	Neutral → Sell
2022-12-07	Eingeleitet	RBC Capital Mkts	Outperform
2022-10-04	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2022-09-28	Hochstufung	Evercore ISI	In-line → Outperform
2022-08-25	Eingeleitet	Credit Suisse	Neutral
2022-07-13	Herabstufung	Barclays	Equal Weight → Underweight
2022-01-18	Hochstufung	Stifel	Hold → Buy
2022-01-11	Hochstufung	Barclays	Underweight → Equal Weight
2022-01-07	Hochstufung	BofA Securities	Underperform → Neutral
2022-01-06	Fortgesetzt	Morgan Stanley	Equal-Weight
2022-01-06	Fortgesetzt	Piper Sandler	Overweight
2021-10-15	Fortgesetzt	Cowen	Outperform
2021-08-19	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-06-01	Hochstufung	Evercore ISI	Underperform → In-line
2021-03-31	Herabstufung	Atlantic Equities	Overweight → Neutral
2021-03-31	Hochstufung	Canaccord Genuity	Hold → Buy
2021-03-03	Eingeleitet	Barclays	Underweight
2020-12-22	Hochstufung	Piper Sandler	Neutral → Overweight
2020-12-17	Hochstufung	BTIG Research	Neutral → Buy
2020-10-13	Herabstufung	Guggenheim	Buy → Neutral
2020-09-30	Eingeleitet	Atlantic Equities	Overweight
2020-09-29	Herabstufung	Wolfe Research	Outperform → Peer Perform
2020-09-22	Herabstufung	Stifel	Buy → Hold
2020-09-22	Herabstufung	UBS	Buy → Neutral
2020-09-21	Hochstufung	Guggenheim	Neutral → Buy
2020-09-21	Herabstufung	JP Morgan	Overweight → Neutral
2020-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2020-08-07	Herabstufung	Evercore ISI	In-line → Underperform
2020-08-07	Herabstufung	Piper Sandler	Overweight → Neutral
2020-07-07	Herabstufung	Guggenheim	Buy → Neutral
2020-04-24	Herabstufung	Citigroup	Buy → Neutral
2020-04-21	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-01-08	Eingeleitet	Wells Fargo	Underweight
2020-01-07	Eingeleitet	Citigroup	Buy
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-11-15	Eingeleitet	Stifel	Buy
2019-10-25	Eingeleitet	Guggenheim	Buy

Alle ansehen

Illumina Inc Aktie (ILMN) Neueste Nachrichten

Jun 18, 2025

Infinity Bio Secures $8M Series A and Acquires Serimmune to Dominate Antibody Reactome Market - Stock Titan

Jun 18, 2025

Jun 17, 2025

DNA/Gene Microarray Market Future Trends and Scope Analysis - openPR.com

Jun 17, 2025

How the DNA Data Storage Market Will Evolve by 2032Growth, - openPR.com

Jun 17, 2025

Jun 16, 2025

Saudia Arabia Introduces Strategic Healthcare Vision and Global Partnerships at BIO 2025 - GlobeNewswire Inc.

Jun 16, 2025

Jun 14, 2025

Next-Gen Diagnostics Drive Biochips Market Growth: Thermo Fisher, Illumina, and PerkinElmer at the Forefront - openPR.com

Jun 14, 2025

Jun 13, 2025

Illumina (ILMN) Price Target Boosted by Canaccord Analyst | ILMN Stock News - GuruFocus

Jun 11, 2025

Video: Two Illumina scientists share their “why” - Illumina

Jun 11, 2025

Breaking Down Illumina: 11 Analysts Share Their Views - Benzinga

Jun 11, 2025

Jun 10, 2025

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - Illumina

Jun 10, 2025

Lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - marketscreener.com

Jun 10, 2025

Jun 09, 2025

Piper Sandler maintains Illumina stock Overweight, $185 target By Investing.com - Investing.com UK

Jun 09, 2025

Long Read Sequencing Market Top Key Players Analysis - openPR.com

Jun 09, 2025

Jun 07, 2025

Gemeinsam Genomik neu denken - Illumina

Jun 07, 2025

Microarray Biochips Market is Booming Worldwide |Illumina,Qiagen,Eppendorf - openPR.com

Jun 07, 2025

Jun 06, 2025

Single-cell Omics Market Projected to Witness Growth with - openPR.com

Jun 06, 2025

Tumor-Derived Exosomes Market Set to Witness Significant - openPR.com

Jun 06, 2025

Hereditary Testing Market Future Business Opportunities - openPR.com

Jun 06, 2025

Next Generation Sequencing Market to Witness Upsurge in Growth - openPR.com

Jun 06, 2025

Jun 05, 2025

Does Illumina (ILMN) Have Good Long-Term Growth Prospects? - Insider Monkey

Jun 05, 2025

Nucleic Acid Isolation and Purification Market Size, Trends & - openPR.com

Jun 05, 2025

Jun 04, 2025

Illumina’s DNA Test Tech Infringes Hospital Patent, Suit Claims - Bloomberg Law News

Jun 04, 2025

Microbiome Sequencing Market Outlook 2025-2029 | Affordable Sequencing Instruments Expand Market Access for Smaller Labs - Yahoo

Jun 04, 2025

Digital Genome Market Deep Research Report on AI-Driven DNA Analysis Trends | Illumina, Thermo Fisher Scientific - openPR.com

Jun 04, 2025

Forensic Genomics Market Research 2025Global Trends, Opportunity, and Forecasts 2020-2030 - GlobeNewswire Inc.

Jun 04, 2025

Jun 03, 2025

Cancer Profiling Market Is Booming So Rapidly 2025-2032 - openPR.com

Jun 03, 2025

Hereditary Testing MarketGlobal Industry Trends, Opportunity, and Forecast, 2020-2030: Key Players Like Illumina and Myriad Genetics Leading the Charge - Yahoo Finance

Jun 03, 2025

Next-Gen RNA Sequencing Market | Personalized Medicine & Future - openPR.com

Jun 03, 2025

Jun 02, 2025

Gene Panel Market Projected to Witness Massive GrowthIllumina, Inc., Thermo Fisher Scientific - openPR.com

Jun 02, 2025

May 31, 2025

Illumina Connected Insights - Technology Networks

May 31, 2025

May 30, 2025